Zobrazeno 1 - 10
of 17
pro vyhledávání: '"L. C. Drinkard"'
Autor:
Jemi Olak, Brian L. Samuels, Daniel J. Haraf, Mark K. Ferguson, Philip C. Hoffman, Harvey M. Golomb, L. C. Drinkard, Everett E. Vokes, Gregory A. Masters, Stuart A. Krauss
Publikováno v:
Journal of Clinical Oncology. 16:2157-2163
PURPOSE The cisplatin-vinorelbine regimen has superior activity in advanced non-small-cell lung cancer (NSCLC). We conducted a phase I trial to identify the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of this regimen with concomi
Autor:
Rosemarie Mick, Brian L. Samuels, Harvey M. Golomb, L. C. Drinkard, Alfred Guaspari, Gregory A. Masters, Ai-ly Hsieh, Philip C. Hoffman, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 15:884-892
PURPOSE We designed a phase I dose-escalation study of vinorelbine on a novel (daily-times-three) schedule with ifosfamide with granulocyte colony-stimulating factor (G-CSF) support to define the dose-limiting toxicity (DLT) and maximum-tolerated dos
Autor:
Mark K. Ferguson, Philip C. Hoffman, Everett E. Vokes, N. J. Lane, L. C. Drinkard, S. Watson, N. J. Vogelzang, Daniel J. Haraf, Harvey M. Golomb
Publikováno v:
Cancer Chemotherapy and Pharmacology. 35:304-312
Concomitant chemoradiotherapy with cisplatin and combination chemotherapy in the neoadjuvant setting have both shown promising results.Purpose: To identify a locally and systemically active concomitant chemoradiotherapy regimen incorporating high-dos
Autor:
Daniel J. Haraf, Everett E. Vokes, Laurie B. Reeder, L. C. Drinkard, Mark K. Ferguson, Philip C. Hoffman
Publikováno v:
Annals of Surgical Oncology. 2:101-106
Background: We designed a trial of intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction to assess tumor response and operability after neoadjuvant chemotherapy and to determine the impact of trimodality therapy
Autor:
John Albertini, Maria Medenica, Joseph M. Baron, Kenneth Beer, Allan L. Lorincz, Timothy J. Swartz, L. C. Drinkard
Publikováno v:
International Journal of Dermatology. 33:860-862
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 9(6)
Summary Purpose: To define the activity and toxicity of preoperative chemotherapy and postoperative concomitant chemoradiotherapy in patients with carcinoma of the esophagus, and to determine the effect on survival in patients treated with this appro
Publikováno v:
Seminars in oncology. 25(1 Suppl 2)
Ifosfamide and vinorelbine have demonstrated single-agent activity against advanced non-small cell lung cancer. The dose-limiting toxicity of each agent is myelosuppression. Several trials have studied this combination to determine its toxicity and e
Publikováno v:
Seminars in oncology. 23(3 Suppl 7)
Current clinical investigations in the palliative care setting for patients with non-small cell lung cancer are focused on new drugs and combinations. The goal of these studies is to identify more effective and/or less toxic therapy. At the Universit
Autor:
P C, Hoffman, G A, Masters, L C, Drinkard, S A, Krauss, B L, Samuels, H M, Golomb, E E, Vokes
Publikováno v:
Seminars in oncology. 23(3 Suppl 6)
Two studies were performed to determine the maximum tolerated dose (MTD) of paclitaxel and vinorelbine, respectively, in combination with a fixed dose of ifosfamide in previously untreated patients with stage IIIB or IV non-small cell lung cancer. Re
Autor:
E E, Vokes, D J, Haraf, G A, Masters, P C, Hoffman, L C, Drinkard, M, Ferguson, J, Olak, S, Watson, H M, Golomb
Publikováno v:
Seminars in oncology. 23(2 Suppl 5)
Most patients with advanced solid tumors of the chest will have local and/or distant disease progression despite standard therapy. Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a